Pitcairn Co. Buys 19,085 Shares of Haleon plc (NYSE:HLN)

Pitcairn Co. grew its stake in Haleon plc (NYSE:HLN) by 8.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 250,187 shares of the company’s stock after purchasing an additional 19,085 shares during the quarter. Pitcairn Co.’s holdings in Haleon were worth $2,647,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Sculptor Capital LP increased its position in Haleon by 67.8% during the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after acquiring an additional 3,592,000 shares during the period. Clearbridge Investments LLC increased its position in Haleon by 8.6% during the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock worth $344,888,000 after acquiring an additional 3,307,009 shares during the period. The Manufacturers Life Insurance Company increased its position in Haleon by 95.5% during the second quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock worth $16,143,000 after acquiring an additional 954,622 shares during the period. Natixis Advisors LLC increased its position in Haleon by 142.5% during the third quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after acquiring an additional 866,070 shares during the period. Finally, Raymond James & Associates increased its position in Haleon by 14.7% during the second quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock worth $33,205,000 after acquiring an additional 515,651 shares during the period. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

HLN stock opened at $9.65 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The firm has a market cap of $43.68 billion, a P/E ratio of 28.38, a P/E/G ratio of 2.88 and a beta of 0.30. The company’s 50-day moving average price is $10.03 and its two-hundred day moving average price is $9.37.

Analyst Ratings Changes

HLN has been the topic of a number of recent research reports. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley raised their target price on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon currently has a consensus rating of “Buy” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.